Vwf (von Willebrand factor) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Vwf (von Willebrand factor) Rattus norvegicus
Analyze
Symbol: Vwf
Name: von Willebrand factor
RGD ID: 621759
Description: Predicted to enable several functions, including identical protein binding activity; integrin binding activity; and protein-folding chaperone binding activity. Involved in several processes, including cellular response to cold; cellular response to lipopolysaccharide; and liver regeneration. Located in extracellular space. Used to study transient cerebral ischemia. Biomarker of hypertension; mesangial proliferative glomerulonephritis; myocardial infarction; pulmonary fibrosis; and type 1 diabetes mellitus. Human ortholog(s) of this gene implicated in several diseases, including Behcet's disease; Bernard-Soulier syndrome; end stage renal disease; essential thrombocythemia; and von Willebrand's disease (multiple). Orthologous to human VWF (von Willebrand factor); PARTICIPATES IN platelet aggregation pathway; cell-extracellular matrix signaling pathway; coagulation cascade pathway; INTERACTS WITH 17alpha-ethynylestradiol; 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil.
Type: protein-coding
RefSeq Status: VALIDATED
Previously known as: von Willebrand factor homolog
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Black Rat
Alliance Orthologs
More Info more info ...
Allele / Splice: Vwfem2Mcwi ; Vwfem3Mcwi ; Vwfem1Mcwi ; Vwfem4Mcwi
Genetic Models: SS-Vwfem2Mcwi-/- ; SD-Vwfem1Mcwi-/- ; SS-Vwfem3Mcwi-/- ; SS-Vwfem4Mcwi
Latest Assembly: GRCr8 - GRCr8 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr84160,042,900 - 160,177,757 (+)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl4160,047,982 - 160,177,757 (+)EnsemblGRCr8
mRatBN7.24158,360,152 - 158,491,539 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl4158,360,152 - 158,491,539 (+)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx4164,595,998 - 164,727,404 (+)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.04160,378,929 - 160,510,343 (+)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.04159,012,985 - 159,144,157 (+)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.04158,085,059 - 158,219,525 (+)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl4158,088,505 - 158,219,523 (+)Ensemblrn6Rnor6.0
Rnor_5.04225,098,521 - 225,229,257 (+)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.44161,723,415 - 161,854,766 (+)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera4147,092,791 - 147,223,711 (+)NCBICelera
RGSC_v3.14162,053,065 - 162,055,090 (+)NCBI
Cytogenetic Map4q42NCBI
JBrowse:




Disease Annotations     Click to see Annotation Detail View
Acute Experimental Pancreatitis  (IEP)
alcohol dependence  (ISO)
alcohol use disorder  (IEP)
alcoholic hepatitis  (ISO)
alcoholic liver cirrhosis  (ISO)
alcoholic pancreatitis  (ISO)
Aortic Injuries  (IEP)
aortic valve stenosis  (ISO)
atrial fibrillation  (ISO)
autism spectrum disorder  (ISO)
autosomal hemophilia A  (ISO)
Behcet's disease  (ISO)
Bernard-Soulier syndrome  (ISO)
bipolar disorder  (ISO)
blood coagulation disease  (ISO)
cardiovascular system disease  (ISO)
carotid artery disease  (ISO)
Chemical and Drug Induced Liver Injury  (IEP,ISO)
Chronic Hepatitis  (ISO)
chronic kidney disease  (ISO)
congestive heart failure  (ISO)
Coronary Disease  (ISO)
Cytomegalovirus Infections  (ISO)
diabetes mellitus  (ISO)
Diabetic Nephropathies  (ISO)
diabetic retinopathy  (ISO)
Drug Hypersensitivity Syndrome  (ISO)
end stage renal disease  (ISO)
endomyocardial fibrosis  (IEP)
Endotoxemia  (IEP)
essential thrombocythemia  (ISO)
exanthem  (ISO)
Experimental Diabetes Mellitus  (IEP)
Experimental Liver Cirrhosis  (IEP,ISO)
factor VIII deficiency  (ISO)
familial combined hyperlipidemia  (ISO)
Femur Head Necrosis  (ISO)
focal segmental glomerulosclerosis  (ISO)
Gastrointestinal Hemorrhage  (IEP)
genetic disease  (ISO)
Hemorrhage  (ISO)
hemorrhagic disease  (ISO)
Hemorrhagic Shock  (IEP)
Herpes Simplex Encephalitis  (ISO)
hypertension  (IEP,ISO)
Hypothermia  (ISO)
Insulin Resistance  (ISO)
Intestinal Reperfusion Injury  (IEP)
intracranial aneurysm  (ISO)
intracranial thrombosis  (ISO)
Kidney Reperfusion Injury  (IEP)
liver cirrhosis  (ISO)
mesangial proliferative glomerulonephritis  (IEP)
metabolic dysfunction-associated steatohepatitis  (ISO)
Metabolic Syndrome  (ISO)
myocardial infarction  (IEP)
obesity  (IEP,ISO)
osteonecrosis  (ISO)
periventricular nodular heterotopia  (ISO)
pulmonary fibrosis  (IEP)
pulmonary hypertension  (ISO)
renal cell carcinoma  (ISO)
schizophrenia  (ISO)
severe acute respiratory syndrome  (ISO)
Spinal Cord Injuries  (IEP)
Stevens-Johnson syndrome  (ISO)
stroke  (ISO)
systemic scleroderma  (ISO)
thrombocytopenia  (ISO)
Thrombocytopenic Purpura  (ISO)
thrombosis  (IMP,ISO)
Thrombotic Microangiopathies  (ISO)
Thrombotic Thrombocytopenic Purpura, Acquired  (ISO)
transient cerebral ischemia  (IDA)
type 1 diabetes mellitus  (IEP)
type 2 diabetes mellitus  (ISO)
Venous Thromboembolism  (ISO)
Von Willebrand Factor, Deficiency  (ISO)
von Willebrand's disease  (ISO,ISS)
von Willebrand's disease 1  (ISO)
von Willebrand's disease 2  (ISO,ISS)
von Willebrand's disease 3  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-dexrazoxane  (ISO)
(S)-nicotine  (ISO)
1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane  (ISO)
1,2-dimethylhydrazine  (ISO)
1-naphthyl isothiocyanate  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-tribromophenol  (ISO)
2,4,6-trinitrobenzenesulfonic acid  (ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (ISO)
2-hydroxypropanoic acid  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3-methylcholanthrene  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
5-aza-2'-deoxycytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
6alpha-methylprednisolone  (ISO)
7,12-dimethyltetraphene  (EXP)
acrolein  (ISO)
aflatoxin B1  (EXP,ISO)
Aflatoxin B2 alpha  (ISO)
aldehydo-D-glucose  (ISO)
alendronic acid  (ISO)
all-trans-retinoic acid  (ISO)
amitrole  (EXP)
ammonium chloride  (EXP)
arsane  (ISO)
arsenic atom  (ISO)
arsenous acid  (ISO)
atorvastatin calcium  (ISO)
benzene  (EXP,ISO)
benzo[a]pyrene  (ISO)
benzo[b]fluoranthene  (ISO)
benzo[e]pyrene  (ISO)
beta-naphthoflavone  (EXP)
bilirubin IXalpha  (ISO)
bis(2-chloroethyl) sulfide  (EXP)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bleomycin A2  (ISO)
Butylbenzyl phthalate  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
calcitriol  (ISO)
cannabidiol  (ISO)
cantharidin  (ISO)
carbon atom  (ISO)
carbon nanotube  (ISO)
CGP 52608  (ISO)
cholesterol  (EXP)
cisplatin  (ISO)
cocaine  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
cortisol  (ISO)
cumene  (ISO)
Cuprizon  (EXP)
curcumin  (EXP)
Curcumol  (ISO)
D-glucose  (ISO)
desmopressin  (ISO)
diarsenic trioxide  (ISO)
dibenz[a,h]anthracene  (ISO)
Dibutyl phosphate  (ISO)
dibutyl phthalate  (EXP)
dioxygen  (ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
elemental carbon  (ISO)
enalapril  (ISO)
erastin  (ISO)
ergosterol  (EXP)
ethanol  (ISO)
fenoldopam  (EXP)
fenvalerate  (EXP)
folic acid  (ISO)
gemcitabine  (ISO)
genistein  (ISO)
gentamycin  (EXP)
gestodene  (ISO)
glucose  (ISO)
graphite  (EXP)
indole-3-methanol  (EXP)
indometacin  (ISO)
isoprenaline  (ISO)
L-methionine  (ISO)
Lasiocarpine  (ISO)
lipopolysaccharide  (ISO)
luteolin  (EXP)
maneb  (ISO)
mercury dibromide  (ISO)
methamphetamine  (EXP)
methapyrilene  (ISO)
methimazole  (EXP)
methoxychlor  (EXP)
methylmercury chloride  (EXP,ISO)
mifepristone  (ISO)
mono(2-ethylhexyl) phthalate  (ISO)
N(gamma)-nitro-L-arginine methyl ester  (ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-nitrosodiethylamine  (EXP)
nicotine  (ISO)
nitrates  (ISO)
Nor-9-carboxy-delta9-THC  (ISO)
okadaic acid  (ISO)
ozone  (EXP,ISO)
p-menthan-3-ol  (EXP)
paracetamol  (EXP,ISO)
paraquat  (ISO)
paricalcitol  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (ISO)
perindopril  (ISO)
phenethyl caffeate  (EXP)
phenylmercury acetate  (ISO)
phytoestrogen  (ISO)
Picein  (ISO)
picoxystrobin  (ISO)
pregnenolone 16alpha-carbonitrile  (EXP)
progesterone  (ISO)
rac-lactic acid  (ISO)
raloxifene  (ISO)
resveratrol  (EXP)
SB 431542  (ISO)
serpentine asbestos  (ISO)
silicon atom  (ISO)
silicon dioxide  (ISO)
simvastatin  (EXP)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sophoraflavanone B  (ISO)
succimer  (ISO)
tamoxifen  (ISO)
tetrachloromethane  (EXP,ISO)
toluene  (EXP)
tremolite asbestos  (ISO)
triadimefon  (EXP)
trichloroethene  (EXP)
triclosan  (ISO)
triphenyl phosphate  (ISO)
triptonide  (ISO)
valproic acid  (ISO)
vincaleukoblastine  (EXP)
vincristine  (EXP)
vitamin E  (ISO)
xanthohumol  (ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function

Molecular Pathway Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. Von Willebrand Factor Gene Variants Associate with Herpes simplex Encephalitis. Abdelmagid N, etal., PLoS One. 2016 May 25;11(5):e0155832. doi: 10.1371/journal.pone.0155832. eCollection 2016.
2. Small bowel ischaemia-reperfusion increases plasma concentrations of oxidised proteins in rats. Abu-Zidan FM, etal., Eur J Surg. 1999 Apr;165(4):383-9.
3. Antiplatelets and profibrinolytic activity of Citrullus colocynthis in control and high-fat diet-induced obese rats: mechanisms of action. Alhawiti NM, Arch Physiol Biochem. 2018 May;124(2):156-166. doi: 10.1080/13813455.2017.1369999. Epub 2017 Aug 31.
4. Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis. Barnes T, etal., Rheumatology (Oxford). 2012 Sep;51(9):1606-9. Epub 2012 May 16.
5. Von Willebrand factor in plasma and in liver tissue after partial hepatectomy in the rat. Baruch Y, etal., J Hepatol 2002 Oct;37(4):471-7.
6. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Bash LD, etal., Am J Kidney Dis. 2009 Apr;53(4):596-605. doi: 10.1053/j.ajkd.2008.10.044. Epub 2008 Dec 24.
7. The genetic association database. Becker KG, etal., Nat Genet. 2004 May;36(5):431-2.
8. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome. Beguin S, etal., J Thromb Haemost. 2004 Jan;2(1):170-6.
9. The vascular biology of the glycoprotein Ib-IX-V complex. Berndt MC, etal., Thromb Haemost. 2001 Jul;86(1):178-88.
10. Von Willebrand factor antigen levels in Behcet disease. Beyan E, etal., Am J Hematol. 2005 May;79(1):70-2.
11. [The clinical and hemostasiological features of chronic hepatitides of different genesis]. Bilalova AR, etal., Ter Arkh. 2014;86(11):50-4.
12. Usefulness of Von Willebrand Factor Activity Indexes to Predict Therapeutic Response in Hypertrophic Cardiomyopathy. Blackshear JL, etal., Am J Cardiol. 2016 Feb 1;117(3):436-42. doi: 10.1016/j.amjcard.2015.11.016. Epub 2015 Nov 19.
13. Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis. Blaya D, etal., Hepatol Int. 2021 Aug;15(4):1006-1017. doi: 10.1007/s12072-021-10165-y. Epub 2021 May 5.
14. Increased deposition of von Willebrand factor in the rat heart after local ionizing irradiation. Boerma M, etal., Strahlenther Onkol. 2004 Feb;180(2):109-16.
15. Haemostatic Profiles are Similar across All Aetiologies of Cirrhosis. Bos S, etal., Thromb Haemost. 2019 Feb;119(2):246-253. doi: 10.1055/s-0038-1676954. Epub 2019 Jan 4.
16. Hypoxia and altered platelet behavior influence von Willebrand factor multimeric composition in secondary pulmonary hypertension. Caramuru LH, etal., Clin Appl Thromb Hemost. 2003 Jul;9(3):251-8.
17. Rosiglitazone does not improve vascular function in subjects with chronic kidney disease. Chan DT, etal., Nephrol Dial Transplant. 2011 Nov;26(11):3543-9. doi: 10.1093/ndt/gfr049. Epub 2011 Mar 4.
18. Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. Chen J, etal., Blood. 2015 Jul 9;126(2):262-9. doi: 10.1182/blood-2014-11-613935. Epub 2015 May 27.
19. Effect of abdominal obesity on prothrombotic tendency in type 2 diabetes. Behavior of clotting factors VII and VIII, fibrinogen and von Willebrand Factor. Coca M, etal., Rom J Intern Med. 2005;43(1-2):115-26.
20. Phase 1-2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow-derived endothelial progenitor cells. D'Avola D, etal., Transl Res. 2017 Oct;188:80-91.e2. doi: 10.1016/j.trsl.2016.02.009. Epub 2016 Feb 24.
21. Effects of long term ethanol consumption mediated oxidative stress on neovessel generation in liver. Das SK, etal., Toxicol Mech Methods. 2012 Jun;22(5):375-82. doi: 10.3109/15376516.2012.666651. Epub 2012 Mar 17.
22. Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure. De Filippis V, etal., Biochem J. 2012 Mar 1;442(2):423-32. doi: 10.1042/BJ20111798.
23. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Eikenboom JC, etal., Blood. 1996 Oct 1;88(7):2433-41.
24. Small intestinal production of nitric oxide is decreased following resuscitated hemorrhage. Fruchterman TM, etal., J Surg Res. 1998 Nov;80(1):102-9.
25. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy. Fujiwara Y, etal., J Atheroscler Thromb. 1998;5(1):21-8.
26. Long Non-coding RNA MALAT1/microRNA-143/VEGFA Signal Axis Modulates Vascular Endothelial Injury-Induced Intracranial Aneurysm. Gao G, etal., Nanoscale Res Lett. 2020 Jun 29;15(1):139. doi: 10.1186/s11671-020-03357-2.
27. Effects of Radix et Rhizoma Rhodiolae Kirilowii on expressions of von Willebrand factor, hypoxia-inducible factor 1 and vascular endothelial growth factor in myocardium of rats with acute myocardial infarction. Gao XF, etal., Zhong Xi Yi Jie He Xue Bao. 2009 May;7(5):434-40. doi: 10.3736/jcim20090507.
28. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
29. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Gill JC, etal., Blood. 2015 Oct 22;126(17):2038-46. doi: 10.1182/blood-2015-02-629873. Epub 2015 Aug 3.
30. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. Gralinski LE, etal., mBio. 2013 Aug 6;4(4). pii: mBio.00271-13. doi: 10.1128/mBio.00271-13.
31. Effect of 3-Phenyl-2-Propene-1-ol on PGE2 release from rat cerebral microvascular endothelial cells stimulated by IL-1beta. Guo JY, etal., Am J Chin Med. 2006;34(4):685-93. doi: 10.1142/S0192415X0600420X.
32. Impact of alpha-tocopherol and vitamin C on endothelial markers in rats with streptozotocin-induced diabetes. Haidara MA, etal., Med Sci Monit. 2004 Feb;10(2):BR41-6.
33. Neurovascular protection conferred by 2-BFI treatment during rat cerebral ischemia. Han Z, etal., Biochem Biophys Res Commun. 2012 Aug 3;424(3):544-8. doi: 10.1016/j.bbrc.2012.06.152. Epub 2012 Jul 6.
34. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor. Hilbert L, etal., Thromb Haemost. 2000 Aug;84(2):188-94.
35. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Hope S, etal., Bipolar Disord. 2009 Nov;11(7):726-34. doi: 10.1111/j.1399-5618.2009.00757.x.
36. Hypothermia-induced activation of the splenic platelet pool as a risk factor for thrombotic disease in a mouse model. Horioka K, etal., J Thromb Haemost. 2019 Oct;17(10):1762-1771. doi: 10.1111/jth.14555. Epub 2019 Jul 17.
37. Molecular evolution of the nuclear von Willebrand factor gene in mammals and the phylogeny of rodents. Huchon D, etal., Mol Biol Evol 1999 May;16(5):577-89.
38. Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome. Ito-Habe N, etal., Int J Hematol. 2011 Jan;93(1):47-52. doi: 10.1007/s12185-010-0732-4. Epub 2010 Dec 9.
39. Stress-induced rise in endothelaemia, von Willebrand factor and hypothalamic-pituitary-adrenocortical axis activation is reduced by pretreatment with pentoxifylline. Jezova D, etal., J Physiol Pharmacol. 2003 Sep;54(3):329-38.
40. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Jilma B, etal., Thromb Haemost. 2010 Sep;104(3):563-70. doi: 10.1160/TH10-01-0027. Epub 2010 Jun 29.
41. Endothelial haemostatic markers in members of families with familial combined hyperlipidemia. Karásek D, etal., Thromb Res. 2009;123(3):466-75. doi: 10.1016/j.thromres.2008.02.011. Epub 2008 Apr 16.
42. Distribution of von Willebrand factor in capillary endothelial cells of rat lungs with pulmonary fibrosis. Kasper M, etal., Exp Toxicol Pathol. 1996 Jun;48(4):283-8.
43. Expression of von Willebrand factor in normal and diseased rat livers and in cultivated liver cells. Knittel T, etal., Hepatology. 1995 Feb;21(2):470-6.
44. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Kunicki TJ, etal., Blood. 2004 Oct 15;104(8):2359-67. Epub 2004 Jun 29.
45. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees. Kunicki TJ, etal., J Thromb Haemost. 2006 Jan;4(1):137-47.
46. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. Lancellotti S, etal., J Thromb Haemost. 2015 Jul;13(7):1226-37. doi: 10.1111/jth.12967. Epub 2015 May 22.
47. Plasma ghrelin and von Willebrand Factor levels in patients with non-traumatic osteonecrosis of the femoral head. Li C, etal., Hip Int. 2015 Jan-Feb;25(1):76-81. doi: 10.5301/HIP.2014.12739. Epub 2014 Oct 19.
48. Anticoagulatory, antiinflammatory, and antioxidative effects of protocatechuic acid in diabetic mice. Lin CY, etal., J Agric Food Chem. 2009 Aug 12;57(15):6661-7. doi: 10.1021/jf9015202.
49. Von Willebrand factor restores impaired platelet thrombogenesis in copper-deficient rats. Lominadze D, etal., J Nutr. 1997 Jul;127(7):1320-7. doi: 10.1093/jn/127.7.1320.
50. Total plasmatic homocysteine and von Willebrand factor in experimental diabetes mellitus. Lopes RD, etal., Arq Bras Cardiol. 2007 Apr;88(4):424-9.
51. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Mancuso DJ, etal., Blood. 1996 Oct 1;88(7):2559-68.
52. Characterization of partial gene deletions in type III von Willebrand disease with alloantibody inhibitors. Mancuso DJ, etal., Thromb Haemost. 1994 Aug;72(2):180-5.
53. Diffuse and persistent blood-spinal cord barrier disruption after contusive spinal cord injury rapidly recovers following intravenous infusion of bone marrow mesenchymal stem cells. Matsushita T, etal., Exp Neurol. 2015 May;267:152-64. doi: 10.1016/j.expneurol.2015.03.001. Epub 2015 Mar 12.
54. Stress-response pathways are altered in the hippocampus of chronic alcoholics. McClintick JN, etal., Alcohol. 2013 Nov;47(7):505-15. doi: 10.1016/j.alcohol.2013.07.002. Epub 2013 Aug 24.
55. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Meigs JB, etal., Diabetes. 2006 Feb;55(2):530-7. doi: 10.2337/diabetes.55.02.06.db05-1041.
56. Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women? Mertens I, etal., Metabolism. 2006 May;55(5):650-5.
57. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
58. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Moake JL Semin Hematol. 2004 Jan;41(1):4-14.
59. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
60. Role of sinusoidal endothelial cells in liver disease. Okanoue T, etal., J Gastroenterol Hepatol. 1995;10 Suppl 1:S35-7. doi: 10.1111/j.1440-1746.1995.tb01794.x.
61. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
62. Kynurenine pathway - a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Pawlak K, etal., Adv Med Sci. 2010;55(2):196-203. doi: 10.2478/v10039-010-0015-6.
63. Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapy. Pequeriaux NC, etal., Nephrol Dial Transplant. 2012 Jun;27(6):2452-7. doi: 10.1093/ndt/gfr735. Epub 2011 Dec 20.
64. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Peyvandi F, etal., N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533.
65. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
66. Heparin-like Effect Associated With Risk of Bleeding, Sepsis, and Death in Patients With Severe Alcohol-Associated Hepatitis. Premkumar M, etal., Clin Gastroenterol Hepatol. 2020 Feb;18(2):486-495.e3. doi: 10.1016/j.cgh.2019.04.057. Epub 2019 May 8.
67. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Rayes J, etal., Blood. 2010 Jun 10;115(23):4870-7. doi: 10.1182/blood-2009-11-254193. Epub 2010 Mar 3.
68. Injury induces increase of von Willebrand factor in rat endothelial cells. Reidy MA, etal., Am J Pathol. 1989 Apr;134(4):857-64.
69. GOA pipeline RGD automated data pipeline
70. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
71. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
72. Comprehensive gene review and curation RGD comprehensive gene curation
73. Aortic endothelial cell von Willebrand factor content, and circulating plasminogen activator inhibitor-1 are increased, but expression of endothelial leukocyte adhesion molecules is unchanged in insulin-dependent diabetic BB rats. Ribau JC, etal., Atherosclerosis. 2000 Apr;149(2):331-42.
74. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. Roldan V, etal., J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14.
75. Characterization of cytomegalovirus disease in solid organ transplant recipients by markers of inflammation in plasma. Rollag H, etal., PLoS One. 2013 Apr 8;8(4):e60767. doi: 10.1371/journal.pone.0060767. Print 2013.
76. Increased levels of endothelial haemostatic markers in patients with coronary heart disease. Schumacher A, etal., Thromb Res. 2002 Jan 1;105(1):25-31.
77. [Effect of the recombinant staphylokinase on pancreatic ischemia in severe acute pancreatitis of rats]. Sha JP, etal., Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007 Aug;19(8):467-70.
78. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies. Shi Q, etal., J Thromb Haemost. 2015 Jul;13(7):1301-9. doi: 10.1111/jth.13001. Epub 2015 Jun 11.
79. Alcohol-induced endothelial changes are associated with oxidative stress and are rapidly reversed after withdrawal. Soardo G, etal., Alcohol Clin Exp Res. 2005 Oct;29(10):1889-98. doi: 10.1097/01.alc.0000183004.28587.23.
80. Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population. Sun W, etal., Int Orthop. 2006 Jun;30(3):143-6. doi: 10.1007/s00264-005-0067-6. Epub 2006 Mar 18.
81. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences Sun YX, etal., Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 May;35(3):315-8.
82. Injury of the renal microvascular endothelium alters barrier function after ischemia. Sutton TA, etal., Am J Physiol Renal Physiol. 2003 Aug;285(2):F191-8. Epub 2003 Apr 8.
83. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Targher G, etal., Diabet Med. 2005 Oct;22(10):1354-8. doi: 10.1111/j.1464-5491.2005.01646.x.
84. Endothelium releases more von Willebrand factor and tissue-type plasminogen activator upon venous occlusion in patients with liver cirrhosis than in normals. Tornai I, etal., Haemostasis. 1993;23(1):58-64. doi: 10.1159/000216853.
85. Platelet adherence to isolated rat hepatic sinusoidal endothelial cells after cold preservation. Upadhya GA and Strasberg SM, Transplantation. 2002 Jun 15;73(11):1764-70.
86. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer. van der Veldt AA, etal., Int J Cancer. 2012 Aug 15;131(4):E484-93. doi: 10.1002/ijc.26456. Epub 2011 Nov 8.
87. Reticuloendothelial activation correlates with disease severity and predicts mortality in severe alcoholic hepatitis. Vijayalekshmi B, etal., Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e329-e334. doi: 10.1097/MEG.0000000000002056.
88. Expression of the molecule detectable by anti-propolypeptide of von Willebrand factor antibody in rat mesangial cells in anti-Thy 1.1 mAb 1-22-3 induced glomerulonephritis: A marker of injured mesangial cells. Wakasugi M, etal., Nephron. 1999;82(4):338-47.
89. Proteomic Identification of Novel Plasma Biomarkers and Pathobiologic Pathways in Alcoholic Acute Pancreatitis. Waldron RT, etal., Front Physiol. 2018 Aug 30;9:1215. doi: 10.3389/fphys.2018.01215. eCollection 2018.
90. [A preliminary study of immuno-electron microscopy of endothelium in cardiovascular system]. Wang JJ and Wang DL, J Formos Med Assoc. 1992 Dec;91 Suppl 4:S275-82.
91. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Wannamethee SG, etal., Atherosclerosis. 2005 Jul;181(1):101-8. doi: 10.1016/j.atherosclerosis.2004.12.031.
92. The differential involvement of von Willebrand factor, fibrinogen and fibronectin in acute experimental thrombosis in rat cerebral and mesenteric microvessels. Yamamoto J, etal., Jpn J Physiol. 1997 Oct;47(5):431-41.
93. Adjuvant effect of antibodies against von Willebrand Factor, fibrinogen, and fibronectin on staphylokinase-induced thrombolysis as measured using mural thrombi formed in rat mesenteric venules. Yamamoto J, etal., Thromb Res. 2000 Mar 1;97(5):327-33.
94. Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosis. Zhang Q, etal., Nephrology (Carlton). 2012 May;17(4):338-45. doi: 10.1111/j.1440-1797.2012.01575.x.
95. [Study on changes of blood coagulation factors in rats with hemorrhagic shock]. Zhang YJ, etal., Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Feb;13(1):110-3.
96. Integrated Analysis of Multiple Microarray Studies to Identify Core Gene-Expression Signatures Involved in Tubulointerstitial Injury in Diabetic Nephropathy. Zhou H, etal., Biomed Res Int. 2022 May 10;2022:9554658. doi: 10.1155/2022/9554658. eCollection 2022.
Additional References at PubMed
PMID:2056120   PMID:3082891   PMID:3087627   PMID:3121636   PMID:6754744   PMID:7721887   PMID:7854452   PMID:8562500   PMID:8565074   PMID:8874190   PMID:9079671   PMID:9689113  
PMID:10764791   PMID:10887119   PMID:10930441   PMID:11071623   PMID:12775718   PMID:12871266   PMID:15824096   PMID:16409464   PMID:16551580   PMID:16735600   PMID:17380206   PMID:17895385  
PMID:18182488   PMID:18433458   PMID:18492805   PMID:19056867   PMID:21037087   PMID:21592973   PMID:21857647   PMID:23376485   PMID:23979707   PMID:24006456   PMID:27068509  


Genomics

Comparative Map Data
Vwf
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr84160,042,900 - 160,177,757 (+)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl4160,047,982 - 160,177,757 (+)EnsemblGRCr8
mRatBN7.24158,360,152 - 158,491,539 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl4158,360,152 - 158,491,539 (+)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx4164,595,998 - 164,727,404 (+)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.04160,378,929 - 160,510,343 (+)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.04159,012,985 - 159,144,157 (+)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.04158,085,059 - 158,219,525 (+)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl4158,088,505 - 158,219,523 (+)Ensemblrn6Rnor6.0
Rnor_5.04225,098,521 - 225,229,257 (+)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.44161,723,415 - 161,854,766 (+)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera4147,092,791 - 147,223,711 (+)NCBICelera
RGSC_v3.14162,053,065 - 162,055,090 (+)NCBI
Cytogenetic Map4q42NCBI
VWF
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh38125,948,877 - 6,124,670 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl125,948,877 - 6,124,770 (-)Ensemblhg38GRCh38
GRCh37126,058,043 - 6,233,836 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36125,928,301 - 6,104,097 (-)NCBIBuild 36Build 36hg18NCBI36
Build 34125,928,307 - 6,104,097NCBI
Celera127,677,686 - 7,853,476 (-)NCBICelera
Cytogenetic Map12p13.31NCBI
HuRef125,910,003 - 6,085,514 (-)NCBIHuRef
CHM1_1126,057,433 - 6,233,298 (-)NCBICHM1_1
T2T-CHM13v2.0125,956,421 - 6,132,275 (-)NCBIT2T-CHM13v2.0
Vwf
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm396125,529,911 - 125,663,642 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl6125,523,737 - 125,663,642 (+)EnsemblGRCm39 EnsemblGRCm39
GRCm386125,552,948 - 125,686,679 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl6125,546,774 - 125,686,679 (+)Ensemblmm10GRCm38
MGSCv376125,502,981 - 125,636,695 (+)NCBIMGSCv37MGSCv37mm9NCBIm37
MGSCv366125,520,072 - 125,652,161 (+)NCBIMGSCv36mm8
Celera6127,212,807 - 127,346,911 (+)NCBICelera
Cytogenetic Map6F3NCBI
cM Map659.32NCBI
Vwf
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049554133,672,470 - 3,819,571 (-)Ensembl
ChiLan1.0NW_0049554133,672,470 - 3,825,588 (-)NCBIChiLan1.0ChiLan1.0
VWF
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v21011,504,401 - 11,680,404 (-)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan11211,501,159 - 11,677,162 (-)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v0126,073,836 - 6,249,806 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.1125,990,612 - 6,166,632 (-)NCBIPanPan1.1PanPan1.1panPan2
PanPan1.1 Ensembl125,990,612 - 6,165,153 (-)EnsemblpanPan2panpan1.1
VWF
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.12738,834,812 - 38,972,614 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl2738,833,837 - 39,320,142 (+)EnsemblcanFam3CanFam3.1
Dog10K_Boxer_Tasha277,641,828 - 7,779,174 (-)NCBIDog10K_Boxer_TashaDog10K_Boxer_Tasha
ROS_Cfam_1.02739,191,850 - 39,329,540 (+)NCBIROS_Cfam_1.0ROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl2739,193,140 - 39,329,536 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.12739,062,625 - 39,200,071 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.02739,104,190 - 39,241,989 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0277,119,622 - 7,257,688 (-)NCBIUU_Cfam_GSD_1.0UU_Cfam_GSD_1.0
Vwf
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_024404945102,910,587 - 103,074,328 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049367091,579,096 - 1,741,754 (+)EnsemblSpeTri2.0 Ensembl
SpeTri2.0NW_0049367091,578,137 - 1,741,877 (+)NCBISpeTri2.0SpeTri2.0SpeTri2.0
VWF
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl564,517,555 - 64,655,938 (+)EnsemblsusScr11Sscrofa11.1
Sscrofa11.1564,516,627 - 64,655,938 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2566,999,793 - 67,078,133 (+)NCBISscrofa10.2Sscrofa10.2susScr3
Pig Cytomap5q21NCBI
VWF
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1115,994,499 - 6,176,949 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl115,994,039 - 6,162,260 (-)EnsemblChlSab1.1 EnsemblchlSab2Vervet-AGM
Vero_WHO_p1.0NW_0236660632,072,116 - 2,236,240 (+)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Vwf
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046248602,858,088 - 2,973,052 (-)EnsemblHetGla_female_1.0 EnsemblhetGla2HetGla_female_1.0 Ensembl
HetGla 1.0NW_0046248602,843,268 - 2,973,888 (-)NCBIHetGla 1.0HetGla 1.0hetGla2
Vwf
(Rattus rattus - black rat)
Black Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Rrattus_CSIRO_v1622,217,359 - 22,342,060 (-)NCBIRrattus_CSIRO_v1

Variants

.
Variants in Vwf
708 total Variants
miRNA Target Status (No longer updated)

Predicted Target Of
Summary Value
Count of predictions:61
Count of miRNA genes:56
Interacting mature miRNAs:60
Transcripts:ENSRNOT00000026643
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (GRCr8)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
6478754Anxrr43Anxiety related response QTL 430.14035locomotor behavior trait (VT:0001392)distance moved per unit of time into, out of or within a discrete space in an experimental apparatus (CMO:0001493)4146370897184426481Rat
724558Plsm2Polydactyly-luxate syndrome (PLS) morphotypes QTL 20.0003hindlimb integrity trait (VT:0010563)hind foot phalanges count (CMO:0001949)4134095016179095016Rat
1582237Kidm34Kidney mass QTL 3440.0001kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)4149763204169799698Rat
6478693Anxrr32Anxiety related response QTL 320.00092locomotor behavior trait (VT:0001392)measurement of voluntary locomotion into, out of or within a discrete space in an experimental apparatus (CMO:0000957)4146370897184426481Rat
6478757Anxrr44Anxiety related response QTL 440.01087locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4155834926184426481Rat
1358364Sradr4Stress Responsive Adrenal Weight QTL 44.92adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)4131384565176384565Rat
10755501Bp390Blood pressure QTL 3902.5arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)427730518170099664Rat
61451Ciaa4CIA Autoantibody QTL 43.1blood autoantibody amount (VT:0003725)calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281)4123870974168870974Rat
1331802Srn5Serum renin concentration QTL 53.045renin activity (VT:0005581)plasma renin activity level (CMO:0000116)4117559384162559384Rat
1331738Bp209Blood pressure QTL 2092.979arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)4140059299181024663Rat
6478700Anxrr33Anxiety related response QTL 330.00896locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4146370897184426481Rat
1298524Oia8Oil induced arthritis QTL 8joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4140059299184426481Rat
10053718Scort25Serum corticosterone level QTL 252.150.0097blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)4157292416184426481Rat
738009Sach4Saccharine consumption QTL 44.90.000016consumption behavior trait (VT:0002069)saccharin intake volume to total fluid intake volume ratio (CMO:0001601)460916264184426481Rat
634335Anxrr16Anxiety related response QTL 167.22locomotor behavior trait (VT:0001392)number of entries into a discrete space in an experimental apparatus (CMO:0000960)494638356168870820Rat
737821Hcar9Hepatocarcinoma resistance QTL 93.7liver integrity trait (VT:0010547)volume of individual liver tumorous lesion (CMO:0001078)4106848959168870974Rat
7411558Bw133Body weight QTL 13313.840.001body mass (VT:0001259)body weight gain (CMO:0000420)4127263297172263297Rat
6478778Anxrr51Anxiety related response QTL 510.25384locomotor behavior trait (VT:0001392)measurement of voluntary locomotion into, out of or within a discrete space in an experimental apparatus (CMO:0000957)4126334185171334185Rat
10401796Kidm48Kidney mass QTL 48kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)4147299608184426481Rat
6478718Anxrr34Anxiety related response QTL 340.00896locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4146370897184426481Rat
6478782Anxrr52Anxiety related response QTL 520.02091locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4155834926184426481Rat
631511Pia7Pristane induced arthritis QTL 74.3joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4123870974168870974Rat
634347Hcar8Hepatocarcinoma resistance QTL 85.8liver integrity trait (VT:0010547)liver tumorous lesion area to total liver area ratio (CMO:0001075)4124700988169700988Rat
6478720Alc23Alcohol consumption QTL 230.00509drinking behavior trait (VT:0001422)ethanol drink intake rate to body weight ratio (CMO:0001616)4155834926184426481Rat
6478785Anxrr53Anxiety related response QTL 530.01397locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4155834926184426481Rat
738031Alc14Alcohol consumption QTL 147.60.00003consumption behavior trait (VT:0002069)ethanol drink intake rate to body weight ratio (CMO:0001616)460916264174095838Rat
1576316Ept5Estrogen-induced pituitary tumorigenesis QTL 53.8pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)4100752691179366077Rat
1581566Eae21Experimental allergic encephalomyelitis QTL 216.2body mass (VT:0001259)maximum body weight loss to initial body weight ratio (CMO:0001400)4137447185182447185Rat
1578674Bmd12Bone mineral density QTL 123.8femur mineral mass (VT:0010011)compact volumetric bone mineral density (CMO:0001730)4137430611182430611Rat
6478728Anxrr36Anxiety related response QTL 360.01061locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4155834926184426481Rat
738016Alc16Alcohol consumption QTL 163.60.00015consumption behavior trait (VT:0002069)ethanol drink intake rate to body weight ratio (CMO:0001616)460916264184426481Rat
1358202Gluco11Glucose level QTL 112.40.02adipocyte glucose uptake trait (VT:0004185)absolute change in adipocyte glucose uptake (CMO:0000873)486709649168870974Rat
61422Cia13Collagen induced arthritis QTL 134.5joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4134199006168870974Rat
634342Cia24Collagen induced arthritis QTL 244.5joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4148121375176967367Rat
6478733Anxrr37Anxiety related response QTL 370.00095locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4155834926184426481Rat
737978Pia23Pristane induced arthritis QTL 235.3joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4123870974168870974Rat
61362Oia2Oil induced arthritis QTL 20.001joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)4140059299184426481Rat
6478737Anxrr38Anxiety related response QTL 380.00159locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4155834926184426481Rat
12798519Anxrr54Anxiety related response QTL 542.540.05locomotor behavior trait (VT:0001392)distance moved per unit of time into, out of or within a discrete space in an experimental apparatus (CMO:0001493)4116184844161184844Rat
2316958Gluco58Glucose level QTL 5810blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)412212457182430611Rat
6478748Anxrr42Anxiety related response QTL 420.28008locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4146370897184426481Rat
12798525Anxrr57Anxiety related response QTL 573.210.05locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)4148834094168870974Rat

Markers in Region
D4Wox36  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.24158,447,303 - 158,447,479 (+)MAPPERmRatBN7.2
Rnor_6.04158,175,129 - 158,175,304NCBIRnor6.0
Rnor_5.04225,185,117 - 225,185,292UniSTSRnor5.0
RGSC_v3.44161,808,751 - 161,808,926UniSTSRGSC3.4
Celera4147,179,655 - 147,179,830UniSTS
Cytogenetic Map4q42UniSTS
Vwf  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.24158,447,823 - 158,448,025 (+)MAPPERmRatBN7.2
Rnor_6.04158,175,649 - 158,175,850NCBIRnor6.0
Rnor_5.04225,185,637 - 225,185,838UniSTSRnor5.0
RGSC_v3.44161,809,271 - 161,809,472UniSTSRGSC3.4
Celera4147,180,175 - 147,180,376UniSTS
Cytogenetic Map4q42UniSTS
RH132777  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.24158,491,246 - 158,491,439 (+)MAPPERmRatBN7.2
Rnor_6.04158,219,233 - 158,219,425NCBIRnor6.0
Rnor_5.04225,228,965 - 225,229,157UniSTSRnor5.0
RGSC_v3.44161,854,469 - 161,854,661UniSTSRGSC3.4
Celera4147,223,419 - 147,223,611UniSTS
Cytogenetic Map4q42UniSTS


Genetic Models
This gene Vwf is modified in the following models/strains:
SS-Vwfem2Mcwi-/-     SD-Vwfem1Mcwi-/-     SS-Vwfem3Mcwi-/-     SS-Vwfem4Mcwi    


Expression

RNA-SEQ Expression

alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
endocrine system
endoderm
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
musculoskeletal system
nervous system
renal system
reproductive system
respiratory system
sensory system
visual system
16 12 67 162 91 90 59 92 59 6 356 192 11 141 81 92 31 17 17

Sequence


Ensembl Acc Id: ENSRNOT00000026643   ⟹   ENSRNOP00000026643
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl4160,047,982 - 160,177,757 (+)Ensembl
mRatBN7.2 Ensembl4158,360,152 - 158,491,539 (+)Ensembl
Rnor_6.0 Ensembl4158,088,505 - 158,219,523 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000116998   ⟹   ENSRNOP00000084421
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl4160,081,103 - 160,177,757 (+)Ensembl
mRatBN7.2 Ensembl4158,394,481 - 158,491,539 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000117299   ⟹   ENSRNOP00000091836
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl4160,047,982 - 160,177,757 (+)Ensembl
mRatBN7.2 Ensembl4158,361,767 - 158,491,539 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000118023   ⟹   ENSRNOP00000079544
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl4160,067,895 - 160,177,757 (+)Ensembl
mRatBN7.2 Ensembl4158,381,564 - 158,491,539 (+)Ensembl
RefSeq Acc Id: NM_053889   ⟹   NP_446341
RefSeq Status: VALIDATED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr84160,046,369 - 160,177,757 (+)NCBI
mRatBN7.24158,360,152 - 158,491,539 (+)NCBI
Rnor_6.04158,088,533 - 158,219,525 (+)NCBI
Rnor_5.04225,098,521 - 225,229,257 (+)NCBI
Celera4147,092,791 - 147,223,711 (+)NCBI
Sequence:
RefSeq Acc Id: XM_063285420   ⟹   XP_063141490
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr84160,042,900 - 160,177,757 (+)NCBI
RefSeq Acc Id: NP_446341   ⟸   NM_053889
- Peptide Label: precursor
- UniProtKB: A0A8J8XVZ5 (UniProtKB/TrEMBL),   A6ILU6 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000026643   ⟸   ENSRNOT00000026643
Ensembl Acc Id: ENSRNOP00000091836   ⟸   ENSRNOT00000117299
Ensembl Acc Id: ENSRNOP00000084421   ⟸   ENSRNOT00000116998
Ensembl Acc Id: ENSRNOP00000079544   ⟸   ENSRNOT00000118023
RefSeq Acc Id: XP_063141490   ⟸   XM_063285420
- Peptide Label: isoform X1
- UniProtKB: A6ILU6 (UniProtKB/TrEMBL),   A0A8J8XVZ5 (UniProtKB/TrEMBL)
Protein Domains
CTCK   VWFA   VWFC   VWFD

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-Q62935-F1-model_v2 AlphaFold Q62935 1-430 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:13693414
Promoter ID:EPDNEW_R3939
Type:single initiation site
Name:Vwf_1
Description:von Willebrand factor
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.04158,088,533 - 158,088,593EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:621759 AgrOrtholog
BioCyc Gene G2FUF-42984 BioCyc
Ensembl Genes ENSRNOG00000019689 Ensembl, ENTREZGENE
Ensembl Transcript ENSRNOT00000026643 ENTREZGENE
Gene3D-CATH 3.40.50.410 UniProtKB/Swiss-Prot
InterPro ECM_Assembly_Org UniProtKB/Swiss-Prot
  VWA_N2 UniProtKB/Swiss-Prot
  VWF_A UniProtKB/Swiss-Prot
  vWFA_dom_sf UniProtKB/Swiss-Prot
NCBI Gene 116669 ENTREZGENE
PANTHER COLLAGEN ALPHA UniProtKB/Swiss-Prot
  VWFA DOMAIN-CONTAINING PROTEIN UniProtKB/Swiss-Prot
Pfam VWA UniProtKB/Swiss-Prot
  VWA_N2 UniProtKB/Swiss-Prot
PhenoGen Vwf PhenoGen
PRINTS VWFADOMAIN UniProtKB/Swiss-Prot
PROSITE VWFA UniProtKB/Swiss-Prot
RatGTEx ENSRNOG00000019689 RatGTEx
SMART VWA UniProtKB/Swiss-Prot
Superfamily-SCOP SSF53300 UniProtKB/Swiss-Prot
UniProt A0A8I5ZNS8_RAT UniProtKB/TrEMBL
  A0A8I6A191_RAT UniProtKB/TrEMBL
  A0A8I6AF98_RAT UniProtKB/TrEMBL
  A0A8J8XVZ5 ENTREZGENE
  A6ILU6 ENTREZGENE, UniProtKB/TrEMBL
  F1M957_RAT UniProtKB/TrEMBL
  Q62935 ENTREZGENE, UniProtKB/Swiss-Prot
UniProt Secondary Q78E31 UniProtKB/Swiss-Prot
  Q9Z0P2 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2010-05-25 Vwf  von Willebrand factor  Vwf  von Willebrand factor homolog  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2009-10-22 Vwf  von Willebrand factor homolog  Vwf  Von Willebrand factor homolog  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-05-15 Vwf  Von Willebrand factor homolog  Vwf  von Willebrand factor  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2006-03-30 Vwf  von Willebrand factor      Symbol and Name status set to approved 1299863 APPROVED
2002-08-07 Vwf  Von Willebrand factor      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_expression protein levels increase after partial hepatectomy 727737